Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 71.46% is in line with its 5-year average of 68.77%, near the high end of its 5-year range (30.76%–74.26%).
14.87% above its 12-month average of 62.21%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 30.76%.
GROSS MARGIN
71.46%
GROSS MARGIN AVG TTM
62.21%
GROSS MARGIN AVG 3Y
70.22%
GROSS MARGIN AVG 5Y
68.77%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+14.87%
CURRENT VS 3Y AVG
+1.76%
CURRENT VS 5Y AVG
+3.91%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 726 covered companies
CURRENT VS SECTOR MEDIAN
+75.88%
vs the sector median at left
Market Cap
$52.46M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$52.47M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$53.01M
Gross Margin
-29.12%
TTM Avg
13.64%
3Y Avg
-48.92%
5Y Avg
-105.92%
Market Cap
$51.28M
Gross Margin
44.89%
TTM Avg
72.44%
3Y Avg
36.22%
5Y Avg
57.48%
Market Cap
$51.34M
Gross Margin
-262.66%
TTM Avg
-246.22%
3Y Avg
-188.06%
5Y Avg
-150.05%
Market Cap
$51.13M
Gross Margin
N/A
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| biote Corp. (BTMD) | $52.48M | 71.46% | 62.21% | 70.22% | 68.77% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.46M | 0.00% | 0.00% | 0.00% | 0.00% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.47M | 0.00% | 0.00% | 0.00% | 0.00% |
| ImageneBio Inc (IMA)vs › | $53.01M | -29.12% | 13.64% | -48.92% | -105.92% |
| Clene Inc. (CLNN)vs › | $51.50M | 78.50% | 79.02% | 83.51% | 77.08% |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.28M | 44.89% | 72.44% | 36.22% | 57.48% |
| Envoy Medical, Inc. (COCH)vs › | $51.34M | -262.66% | -246.22% | -188.06% | -150.05% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.13M | N/A | 50.00% | 25.00% | 16.67% |
| INmune Bio, Inc. (INMB)vs › | $50.78M | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
71.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 30.76% |
| 2026-03-31 | 68.88% |
| 2025-12-31 | 68.03% |
| 2025-09-30 | 71.77% |
| 2025-06-30 | 71.60% |
| 2025-03-31 | 74.26% |
| 2024-12-31 | 71.30% |
| 2024-09-30 | 70.47% |
| 2024-06-30 | 68.98% |
| 2024-03-31 | 71.26% |
| 2023-12-31 | 69.36% |
| 2023-09-30 | 68.90% |
| 2023-06-30 | 67.87% |
| 2023-03-31 | 69.05% |
| 2022-12-31 | 65.33% |
| 2022-09-30 | 68.22% |
| 2022-06-30 | 67.27% |
| 2022-03-31 | 66.95% |
| 2021-12-31 | 63.97% |
| 2021-09-30 | 65.45% |
| 2021-06-30 | 66.50% |
| 2021-03-31 | 63.98% |
| 2020-12-31 | 63.34% |
